The U.S. Senate gave unanimous approval to a bipartisan bill to “cut the red tape” that stalls scientific research into the medical properties of cannabis and cannabidiols. According to a news release issued Thursday by U.S. Sen. Dianne Feinstein, a California Democrat, the Senate approved S. 253 on a voice vote. The measure – which
U.S. Food and Drug Administration
U.S. health and trade authorities this week issued a record seven warning letters in a single day to companies making CBD, the biggest federal action against the industry in over a year. Warning letters from the Food and Drug Administration and the Federal Trade Commission targeted companies making COVID-related claims. It was the first time
U.S. health authorities are signing off on human trials of CBD to treat opioid addiction. The U.S. Food and Drug Administration gave the green light this week to Ananda Scientific to start human testing of its CBD drug Nantheia ATL5, the company announced. The trials will be run out of UCLA and are funded by
(This opinion column appears in the February issue of Marijuana Business Magazine.) Everyone in the hemp industry knows the story of Charlotte’s Web: A group of well-meaning brothers working under Colorado’s medical marijuana system developed a cannabis strain that worked miracles on a sick little girl named Charlotte. Word spread about the awe-inspiring results of
Hemp businesses walk a fine line when describing the health benefits of their products: Make a claim without evidence or wording that misleads consumers, and soon the legal fees will pile up. The U.S. Food and Drug Administration has guidelines for acceptable claims to make on labels for dietary supplements – the closest fit for
U.S. drug regulators have withdrawn their proposal to regulate over-the-counter CBD, handing the industry another setback after years of delay from the Food and Drug Administration. The proposal in question appears to be on pause because of the changing administration. The delay was widely anticipated but still frustrating for CBD operators awaiting the rules. The